Advertisement
Advertisement
Bendared

Bendared

bendamustine

Manufacturer:

Dr. Reddy's Lab

Distributor:

DKSH
Concise Prescribing Info
Contents
Bendamustine HCl
Indications/Uses
Monotherapy in patients w/ chronic lymphocytic leukaemia; indolent B-cell non-Hodgkin's lymphomas that has progressed during or w/in 6 mth of rituximab or rituximab-containing treatment regimen.
Dosage/Direction for Use
Monotherapy for chronic lymphocytic leukaemia 100 mg/m2 IV infusion over 30-60 min on days 1 & 2 every 4 wk. Monotherapy for indolent non-Hodgkin's lymphomas refractory to rituximab 120 mg/m2 IV infusion over 30-60 min on days 1 & 2 every 3 wk. Moderate hepatic impairment Reduce dose to 30%.
Contraindications
Hypersensitivity. Severe bone marrow suppression & blood count alterations (leukocyte &/or platelet values dropped to <3,000/microliter or <75,000/microliter, respectively). Infections especially leukocytopenia. Yellow fever vaccination. Major surgery <30 days prior to treatment. Jaundice; severe hepatic impairment (serum bilirubin >3 mg/dL). Lactation.
Special Precautions
Discontinue use if severe skin reactions occur; signs of opportunistic infections are present. Severe anaphylactic & anaphylactoid reactions. Myelosuppression; concurrent or history of cardiac disease; nausea, vomiting; tumor lysis syndrome. Test for HBV infection prior to initiation. Closely monitor blood chemistry particularly K & uric acid levels prior to therapy. Ensure adequate hydration. Avoid extravasation. May affect ability to drive & use machines. Moderate hepatic & severe renal impairment. May cause irreversible infertility. Women of childbearing potential should use effective contraception. Male patients should use effective contraception during & up to 6 mth after last dose. Not to be used during pregnancy & lactation. Ped patients.
Adverse Reactions
Infection; leukopenia, thrombocytopenia, lymphopenia; headache; nausea, vomiting; mucosal inflammation, fatigue, pyrexia; decreased Hb, increased creatinine & urea. Tumor lysis syndrome; haemorrhage, anaemia, neutropenia; hypersensitivity; insomnia, dizziness; arrhythmia, cardiac dysfunction eg, palpitations, angina pectoris; hypotension, HTN; pulmonary dysfunction; diarrhoea, constipation, stomatitis; alopecia, skin disorders, urticaria; amenorrhea; pain, chills, dehydration, anorexia; increased AST, ALT, alkaline phosphatase & bilirubin, hypokalemia.
Drug Interactions
Potentiated effect w/ myelosuppressive agents. Excessive immunosuppression w/ risk of lymphoproliferation w/ cyclosporine or tacrolimus. Reduced Ab formation & increased risk of infection by cytostatics. Concomitant use w/ CYP1A2 inhibitors eg, fluvoxamine, ciprofloxacin, acyclovir, cimetidine.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01AA09 - bendamustine ; Belongs to the class of alkylating agents, nitrogen mustard analogues. Used in the treatment of cancer.
Presentation/Packing
Form
Bendared infusion conc 180 mg/4 mL
Packing/Price
1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement